6 results
Primary:To assess the effect of various degrees of impairment in hepatic function as measured by NCICTEPcriteria, on the pharmacokinetics of panobinostat.Secondary:To assess the effect of various degrees of hepatic functions on the safety of…
Given the medical need for improved treatment strategies for patients with previously treated and relapsed MM, the purpose of this phase III study is to compare treatment with bortezomib/dexamethasone + panobinostat to bortezomib/dexamethasone +…
This clinical trial will test the safety and performance of the Spinal Modulation Neurostimulator System in the treatment of chronic pain.Outcomes:Primary Outcomes: 1) Safety as determined by adverse event reporting2) Device performance as…
As results from a recently completed radio-labeled human ADME study [CLBH589B2108] in patients indicated that both kidney and liver are involved in the elimination and metabolism of panobinostat, understanding the impact of altered organ function…
Primary: To allow continued use of panobinostat to patients receiving single agent therapy with panobinostat in a Novartis-sponsored study.Secondary: To collect long term data on SAEs.
To investigate the ability of PF-06372865 to demonstrate analgesic properties in healthy subjects for pre-specified primary endpoints using a panel of pain tests.